skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

99+ Total results for product and free and sample content found

Scrip

Ready, Set, Lowest: Who Won China's Latest Drug Bidding War?

By Brian Yang 18 Oct 2019

Ready, Set, Lowest: Who Won China's Latest Drug Bidding War?

Multinationals are feeling the heat to win in China's latest drug procurement battle. The winning prices have surprised even previous winners and may have a profound and long-lasting impact on the pharma sector.

Topic Deal trends Strategy

Scrip

Survival Data Boost Lilly & Novartis's CDK4/6 Assault On Pfizer's Ibrance In Metastatic Breast Cancer

By Alex Shimmings 18 Oct 2019

Survival Data Boost Lilly & Novartis's CDK4/6 Assault On Pfizer's Ibrance In Metastatic Breast Cancer

Pfizer’s dominance of the CDK4/6 inhibitor market will come under renewed pressure as the MONALEESA-3 and MONARCH-2 studies for Novartis’s Kisqali and Lilly’s Verzenio presented at ESMO confirmed their survival benefits in advanced hormone-receptor-positive, HER2-negative breast cancer. The data firmly push the drug class into front-line advanced setting in these patients.

Topic Cancer Drug development landscape Research

Scrip

Woodford Debacle Is A Test Of UK Biotech's Resilience

By Andrew McConaghie 18 Oct 2019

Woodford Debacle Is A Test Of UK Biotech's Resilience

Investor's Downfall is Unwelcome Distraction: As once-star investment funds fail, another major investor argues this is opportunity for UK biotech to demonstrate staying power.

Topic BioPharmaceutical Company analysis

Scrip

Progress Being Made With Cell And Gene Therapy Market Access, But Challenges Remain

By Mandy Jackson 18 Oct 2019

Progress Being Made With Cell And Gene Therapy Market Access, But Challenges Remain

Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.

Topic Cell and gene therapy Drug development landscape

Scrip

Hypoxia Nobel Prize Winners: How Biopharma Is Using Their Research

By Andrew McConaghie 18 Oct 2019

Hypoxia Nobel Prize Winners: How Biopharma Is Using Their Research

Academic research has once again demonstrated itself to the oxygen of inspiration for industry drug innovation, including a blockbuster-in-waiting.

Topic Research BioPharmaceutical

Scrip

Payers Must Brace For Coming Wave Of Cell And Gene Therapies

By Mandy Jackson 18 Oct 2019

Payers Must Brace For Coming Wave Of Cell And Gene Therapies

One regenerative medicine for an ultra-rare disease may have a small impact, but payers will be flooded with dozens of new cell and gene therapies over the next few years. Enzyvant, Novartis and Spark share how they are positioning their complex products.

Topic Cell and gene therapy

Generics Bulletin

Finalists revealed for CPhI Worldwides eagerly anticipated 2019 Awards

17 Oct 2019

London, 17 October 2019: CPhI Worldwide announces the finalists for the CPhI Pharma Awards. The shortlist spans 13 different categories across the full spectrum of the pharmaceutical supply chain, including Formulation, Packaging and Lifetime Achievement Awards.

Biomedtracker, Meddevicetracker

Q4 2019 Outlook Report Extract

16 Oct 2019

What major drug catalysts and events can you expect to see this quarter? Get a view of what's to come with an extract from the full report.

Topic Clinical trials Drug development landscape

Meddevicetracker

Q3 2019 Catalyst Roundup

16 Oct 2019

What were the outcomes of critical catalysts featured in Meddevicetracker’s Q3 2019 Outlook Report? Find out in the Catalyst Roundup: A Review of Select Catalysts from Last Quarter’s Outlook Report. This data-rich graphic is available now – for free.

Topic Drug approval

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: